Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (691-700 of 709) with videos related to

Pageof 71
Sort By:
Earth, Planets, and Space : EPS|January 28, 2020
Venus looks different from day to night across wavelengths: morphology from Akatsuki multispectral imagesSanjay S Limaye, Shigeto Watanabe, Atsushi Yamazaki, et al.
BMJ Open|June 2, 2026
Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocolKeisuke Koroki, Masaru Wakatsuki, Sadahisa Ogasawara, et al.
International Journal of Cardiology|January 25, 2024
Geographic disparity of pathophysiological coronary artery disease characteristics: Insights from ASET trialsNozomi Kotoku, Kai Ninomiya, Shinichiro Masuda, et al.
Investigational New Drugs|June 6, 2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, et al.
Heart and Vessels|February 22, 2018
Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trialKoji Kuroda, Toshiro Shinke, Hiromasa Otake, et al.
Journal of Cancer|June 17, 2022
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring <i>CTNNB1</i> Mutation in Early Clinical ExperienceKeita Ogawa, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.
Cardiovascular Intervention and Therapeutics|March 30, 2018
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018Yukio Ozaki, Yuki Katagiri, Yoshinobu Onuma, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cellsTerunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 14, 2023
Preprocedural physiological assessment of coronary disease patterns to predict haemodynamic outcomes post-PCINozomi Kotoku, Kai Ninomiya, Shinichiro Masuda, et al.
BMC Gastroenterology|April 2, 2023
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceSae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, et al.
Pageof 71

Showing results (691-700 of 709) with videos related to

Sort By:
Pageof 71
Earth, Planets, and Space : EPS|January 28, 2020
Venus looks different from day to night across wavelengths: morphology from Akatsuki multispectral imagesSanjay S Limaye, Shigeto Watanabe, Atsushi Yamazaki, et al.
BMJ Open|June 2, 2026
Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocolKeisuke Koroki, Masaru Wakatsuki, Sadahisa Ogasawara, et al.
International Journal of Cardiology|January 25, 2024
Geographic disparity of pathophysiological coronary artery disease characteristics: Insights from ASET trialsNozomi Kotoku, Kai Ninomiya, Shinichiro Masuda, et al.
Investigational New Drugs|June 6, 2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, et al.
Heart and Vessels|February 22, 2018
Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trialKoji Kuroda, Toshiro Shinke, Hiromasa Otake, et al.
Journal of Cancer|June 17, 2022
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring <i>CTNNB1</i> Mutation in Early Clinical ExperienceKeita Ogawa, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.
Cardiovascular Intervention and Therapeutics|March 30, 2018
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018Yukio Ozaki, Yuki Katagiri, Yoshinobu Onuma, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cellsTerunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 14, 2023
Preprocedural physiological assessment of coronary disease patterns to predict haemodynamic outcomes post-PCINozomi Kotoku, Kai Ninomiya, Shinichiro Masuda, et al.
BMC Gastroenterology|April 2, 2023
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceSae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, et al.
Pageof 71